Shuren: New Uncertainty Draft Guidance Looks Beyond p-Values
Executive Summary
After years of talking about how to tackle uncertainty of benefit/risk in devices under review, US FDA has released a guidance on the issue. Medtech Insight caught up with FDA device center director Jeff Shuren at a meeting in Washington, DC, to talk about the guidance and what he hopes will come of it.
You may also be interested in...
Preferential Treatment: US FDA Asks Patients For Their Input
As the agency continues to incorporate more patient-preference data into its regulatory process, it is asking stakeholders on the kinds of diseases and other factors it should consider when evaluating patient-preference information. The feedback is ultimately meant to inform regulators and sponsors about what patients want as they develop products.
FDA Guidance Mulls Uncertainty In Device Reviews
New draft guidelines from US FDA offer a framework on how the agency will review device applications that include some uncertainty as to the benefits and risks of the technology.
Final Guidance Encourages Use Of Patient Preference In Device Applications
US FDA released a final guidance aimed at helping sponsors and other stakeholders interested in using patient-preference information to make their case for a device application. The agency has decided to keep its labeling recommendation in the final guidance despite industry objections.